Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Day to day Temporary Positions That Compensate Fairly in the US - 2Dominating Online Entertainment Showcasing: 7 Hints for Organizations
- 3Turkey key underlying issue as Israel, Greece, Cyprus hold summit
- 4Solid Living Tips: Experiences from a Wellness Fan
- 5Israel says soldiers wounded in Gaza fighting amid fragile truce
- The top astronomical discoveries of 2025
- Netanyahu expects Iran's leadership to fall
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- Top 10 Smash hit Computer games of the Year
- Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike
- December's overlooked meteor shower peaks next week — will the Ursids surprise us?
- Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- 6 Monetary Arranging Administrations for Your Necessities
